Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
138 hedge funds and large institutions have $383M invested in Insys Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 40 increasing their positions, 44 reducing their positions, and 15 closing their positions.
93% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 15
11% more funds holding
Funds holding: 124 → 138 (+14)
9% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 44
13% less capital invested
Capital invested by funds: $442M → $383M (-$58.9M)
18% less call options, than puts
Call options by funds: $4.89M | Put options by funds: $5.95M
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$12.4M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.89M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.58M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
+$3.1M |
| 5 |
State Street
Boston,
Massachusetts
|
+$2.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
-$10.2M |
| 2 |
GAM
Gotham Asset Management
New York
|
-$9.38M |
| 3 |
1WCM
12 West Capital Management
New York
|
-$8.07M |
| 4 |
Goldman Sachs
New York
|
-$7.1M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$4.04M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Teacher Retirement System of Texas
Austin,
Texas
| – | -$39K | -3,027 | Closed |
|
|
GBT
152
Grove Bank & Trust
Miami,
Florida
| – | -$3K | -200 | Closed |
|
153
JP Morgan Chase
New York
| – | -$760 | -50 | -57% |
|
INSY Hedge Fund Activity: Q3 2016 in Review
138 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q3 2016, worth a combined $383M — down 13% from $442M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new INSY positions and 15 closed out — a net gain of 14 holders — while 40 added to existing stakes and 44 trimmed.
The largest buyer was OrbiMed, adding an estimated $12.4M. The largest seller was HealthInvest Partners, exiting entirely with an estimated $10.2M sold.
- 138 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q3 2016, up from 124 in Q2 2016.
- Funds reported $383M of Insys Therapeutics, Inc. stock for Q3 2016, down 13% quarter-over-quarter.
- 29 funds opened new Insys Therapeutics, Inc. positions in Q3 2016 and 15 closed out, a net change of +14 holders.
- The largest Insys Therapeutics, Inc. buyer in Q3 2016 was OrbiMed, an estimated $12.4M added.
- The largest Insys Therapeutics, Inc. seller in Q3 2016 was HealthInvest Partners, an estimated $10.2M sold.
Based on aggregated 13F filings for Q3 2016.